The Effect of Eplerenone in Chronic Central Serous Chorioretinopathy Refractory to Photodynamic Therapy

References

• Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86:126–145. doi:10.1111/j.1600-0420.2007.00889.x.
   PubMed Web of Science ®Google Scholar
• Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye. 2010;24:1743–1756. doi:10.1038/eye.2010.130.
   PubMed Web of Science ®Google Scholar
• Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. 2015;12:CD011841.
   Google Scholar
• Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58:103–126. doi:10.1016/j.survophthal.2012.07.004.
   PubMed Web of Science ®Google Scholar
• Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol. 2013;41:201–214. doi:10.1111/j.1442-9071.2012.02848.x.
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Retina. 2012;32(Suppl 1):709. doi:10.1097/IAE.0b013e31823ff9a6.
   PubMedGoogle Scholar
• Chatziralli I, Kabanarou SA, Parikakis E, Chatzirallis A, Xirou T, Mitropoulos P. Risk factors for central serous chorioretinopathy: multivariate approach in a case-control study. Curr Eye Res. 2017;42:1069–1073. doi:10.1080/02713683.2016.1276196.
   PubMed Web of Science ®Google Scholar
• Miki A, Kondo N, Yanagisawa S, Bessho H, Honda S, Negi A. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology. 2014;121:1067–1072. doi:10.1016/j.ophtha.2013.11.020.
   PubMed Web of Science ®Google Scholar
• de Jong EK, Breukink MB, Schellevis RL, et al. Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology. 2015;122:562–570. doi:10.1016/j.ophtha.2014.09.026.
   PubMed Web of Science ®Google Scholar
• Moschos MM, Gazouli M, Gatzioufas Z, et al. Prevalence of the complement factor H and GSTM1 genes polymorphisms in patients with central serous chorioretinopathy. Retina. 2016;36:402–407. doi:10.1097/IAE.0000000000000693.
   PubMed Web of Science ®Google Scholar
• Quin G, Liew G, Ho IV, Gillies M, Fraser-Bell S. Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin Exp Ophthalmol. 2013;41:187–200. doi:10.1111/j.1442-9071.2012.02847.x.
   PubMed Web of Science ®Google Scholar
• Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122:2672–2679. doi:10.1172/JCI61427.
   PubMed Web of Science ®Google Scholar
• Chatziralli I, Vlachodimitropoulou A, Daoula C, et al. Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature. Int J Retina Vitreous. 2018;4:33. doi:10.1186/s40942-018-0137-8.
   PubMedGoogle Scholar
• Yang D, Eliott D. Systemic mineralocorticoid antagonists in the treatment of central serous chorioretinopathy. Semin Ophthalmol. 2017;32:36–42. doi:10.1080/08820538.2016.1228418.
   PubMed Web of Science ®Google Scholar
• Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2013;33:2096–2102. doi:10.1097/IAE.0b013e318297a07a.
   PubMed Web of Science ®Google Scholar
• Singh RP, Sears JE, Bedi R, Schachat AP, Ehlers JP, Kaiser PK. Oral eplerenone for the management of chronic central serous chorioretinopathy. Int J Ophthalmol. 2015;8:310–314. doi:10.3980/j.issn.2222-3959.2015.02.17.
   PubMed Web of Science ®Google Scholar
• Salz DA, Pitcher JD 3rd, Hsu J, et al. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Ophthalmic Surg Lasers Imaging Retina. 2015;46:439–444. doi:10.3928/23258160-20150422-06.
   PubMed Web of Science ®Google Scholar
• Breukink MB, Den Hollander AI, Keunen JE, Boon CJ, Hoyng CB. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Acta Ophthalmol. 2014;92:488–490. doi:10.1111/aos.12311.
   PubMed Web of Science ®Google Scholar
• Leisser C, Hirnschall N, Hackl C, Plasenzotti P, Findl O. Eplerenone in patients with chronic recurring central serous chorioretinopathy. Eur J Ophthalmol. 2016;26:479–484. doi:10.5301/ejo.5000727.
   PubMed Web of Science ®Google Scholar
• Cakir B, Fischer F, Ehlken C, et al. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2016;254:2151–2157. doi:10.1007/s00417-016-3373-3.
   PubMed Web of Science ®Google Scholar
• Sampo M, Soler V, Gascon P, et al. Eplerenone treatment in chronic central serous chorioretinopathy. J Fr Ophtalmol. 2016;39:535–542. doi:10.1016/j.jfo.2016.01.008.
   PubMed Web of Science ®Google Scholar
• Gergely R, Kovács I, Schneider M, et al. Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes. Retina. 2017;37:1084–1091. doi:10.1097/IAE.0000000000001303.
   PubMed Web of Science ®Google Scholar
• Rahimy E, Pitcher JD 3rd, Hsu J, et al. A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ECSELSIOR). Retina. 2018;38:962–969. doi:10.1097/IAE.0000000000001649.
   PubMed Web of Science ®Google Scholar
• Pichi F, Carrai P, Ciardella A, Behar-Cohen F, Nucci P. Central serous chorioretinopathy study group. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol. 2017;37:1115–1125. doi:10.1007/s10792-016-0377-2.
   PubMed Web of Science ®Google Scholar
• Schwartz R, Habot-Wilner Z, Martinez MR, et al. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol. 2017;95:610–618. doi:10.1111/aos.13491.
   Web of Science ®Google Scholar